a, Intraocular tumour 4 months after Rb-depleted cone precursor xenograft. b, Summary of subretinal xenograft groups 1, 2 and 3. Sample size was as needed to assess tumour phenotypes. Mice were randomly assigned to different xenograft regimens and the investigator blinded to the assignment until the tumour analyses. Two mice with early death were excluded from the analyses. c, SNP-array analysis of one Rb/p130-depleted (tumour 1) or one Rb-depleted (tumour 2) cone-precursor-derived tumours from xenograft group 3, revealing no megabase-size loss of heterozygosity or copy number alterations . d, qPCR analysis of pLKO shRNA vector copy number in tumours derived from Rb/p130-depleted cone precursors (m-Cone1, m-Cone2) or from Rb/p130-depleted unsorted retinal cells (m-All3, m-All4), or in mouse ocular tissue (m-Cone-SCR), Y79 cells, or FW19 retina (normal). All tumours retained RB1 and/or p130 shRNA vector sequences, confirming their engineered cone precursor origin. e, qPCR analysis of MDM2, MDM4, RB1 and MYCN copy number in three cone-derived tumours and normal retina (n = 6). DNA copy number data (d, e) are representative of two analyses. Values and error bars are mean and s.d. of triplicate assays.